- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 5/44 - GlucocorticosteroidsDrugs increasing or potentiating the activity of glucocorticosteroids
Patent holdings for IPC class A61P 5/44
Total number of patents in this class: 127
10-year publication summary
|
3
|
2
|
3
|
3
|
7
|
4
|
12
|
6
|
6
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Ardelyx, Inc. | 115 |
5 |
| Chiesi Farmaceutici S.p.A. | 964 |
5 |
| Corcept Therapeutics, Inc. | 366 |
5 |
| Nicox S.A. | 146 |
5 |
| Gilead Sciences, Inc. | 2171 |
4 |
| Santen Pharmaceutical Co., Ltd. | 592 |
3 |
| Schering Corporation | 380 |
3 |
| Mallinckrodt ARD IP Limited | 7 |
3 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 338 |
3 |
| Sparrow Pharmaceuticals, Inc. | 13 |
3 |
| Merck & Co., Inc. | 201 |
2 |
| Boehringer Ingelheim International GmbH | 4567 |
2 |
| Boehringer Ingelheim Pharma GmbH & Co. Kg | 453 |
2 |
| Board of Regents, The University of Texas System | 6032 |
2 |
| Case Western Reserve University | 1867 |
2 |
| DuoCort Pharma AB | 2 |
2 |
| Eli Lilly and Company | 4016 |
2 |
| Jiangsu Simcere Pharmaceutical Co., Ltd | 125 |
2 |
| MetrioPharm AG | 51 |
2 |
| Neurocrine Biosciences, Inc. | 449 |
2 |
| Other owners | 68 |